Heart Failure Drugs Market: Information By Type (Beta-Blockers, ACE Inhibitors, Angiotensin-Receptor Neprilysin Inhibitors (ARNI), Angiotensin Receptor Blockers (ARBs), Diuretic, Others), By End-User (Hospitals, Specialty Centers and others) - Forecast till 2027

Heart Failure Drugs Market Overview:

Heart Failure Drugs Market size is anticipated to register a 5.9% CAGR to reach USD 18.10 Billion by 2030. Heart failure ailment has motivated drug manufacturers to pursue better treatment options, partially because the products they formulate will be received well in this mounting market due to increasingly high detection rates globally.

COVID-19 Analysis

The COVID-19 has passed heart disease as the top cause of mortality over the past year. This fact has led several pharma firms to try out innovative and ingenious solutions to counter heart failure. For instance, the injections from Moderna and the collaboration of Pfizer and BioNTech use genetic material termed messenger RNA to alter the body's cells into vaccine factories efficiently. In no way, the tactic had been used outside of clinical experiments and seeing its success against the coronavirus stunned even some of its most keen backers. This development is estimated to spur mRNA companies to harness the technology for heart failure treatment, flu vaccines, cystic fibrosis, and perhaps HIV.

Market Dynamics

Drivers

Rising Cardiovascular Disorders

The alarmin surge in cardiac ailments is estimated to create abundant opportunities for the heart failure drugs market size development in the coming period.

Launch of Several Heart Failure Drugs

The presence of a robust pipeline of drugs that are continually being launched to tackle the ailment of heart failure is estimated to guide the market's growth in the impending period.

Opportunities

Expanding Drugs for Heart Failure With Preserved Ejection Fraction

The enhanced research directed towards treating preserved ejection fraction heart failure with effective drugs is likely to promote the heart failure drugs market.

Challenges

Side-Effects of The Medication

The increased occurrence of severe side effects in some cases is estimated to restrict the heart failure drugs market.

Segment Overview

By Type

The ACE Inhibitors segment is likely to steer the market in the forecast period's duration.

By End-Users

The hospital segment is projected to have the dominant stake because these medications are often prescribed after a thorough diagnosis, which is often conducted at these institutions.

Regional Analysis

Americas  Region to Be Spurred By Elevated Cases

The Americas regional market was the major market for heart failure drugs. The Americas' heart failure drug market growth is due to the elevated prevalence of cardiovascular disorders, increasing healthcare spending, and intensifying obesity cases. Besides, the continually changing lifestyle habits such as excessive alcohol consumption, damaging dietary habits smoking, obesity, and absence of physical activity make individuals more vulnerable to arrhythmia and heart failure, thus driving the regional market growth.

European Region to Seek Development With New Drug Approvals

Europe is the next chief market for heart failure drugs. It is expected to record a positive development rate throughout the forecast period due to mounting cardiovascular disorders and swelling cigarette smoking population. Also, the intensifying older population in the European Union is compelling heart failure drugs market in the European region.

APAC to Show Confident Development

The Asia Pacific region is projected to signify the uppermost market growth capacity over the forecast period owing to the mounting patient pool and growing technological developments. The APAC region's fast development is due to the collective per capita income and government proposals to enhance healthcare value, and growing cardiovascular diseases will boost the region's overall development.

Competitive Landscape

The Prominent Players in the Global Heart Failure Drugs Market are

• Amgen Inc. (U.S.),


• AstraZeneca (U.K.),


• Novartis AG (Switzerland),


• Boehringer Ingelheim International GmbH (Germany),


• Johnson & Johnson Services, Inc. (U.K.),


• Bristol-Myers Squibb Company (U.S.),


• Merck Sharp & Dohme Corp. (U.S.),


• Pfizer, Inc. (U.S.),


• Gilead Sciences, Inc. (California)

Recent Developments

Jan 2021 According to two new studies, an exceptional diabetes drug has shown heart-related benefits in people with diabetes who also have recently deteriorating heart failure or kidney disease. The drug sotagliflozin (Zynquista) belongs to a class of SGLT2 inhibitors, which cause the kidneys to release more sugar into the urine. The drug is also an SGLT1 inhibitor, meaning it decreases sugar assimilation in the intestines. This dual-action lowers high blood sugar, the mark of diabetes. In people with kidney disease, sotagliflozin reduced the total number of deaths from cardiovascular disease and hospitalizations and urgent visits for heart failure by about 26% compared with a placebo.

Jan 2021 Bayer and Merck & Co's heart failure drug vericiguat has been approved by the FDA under the brand name Verquvo, in a progressively competitive market. Verquvo has been approved to cut the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction less than 45%. The drug can be consumed after hospitalization for heart failure or in patients in want of intravenous diuretics. But the drug is entering an increasingly competitive market, where Novartis and AstraZeneca are competing for supremacy. Entresto (sacubitril+valsartan) was FDA-approved in patients with reduced ejection fraction five years ago.

Jan 2021 Scientists discovered that the standard chemotherapy drug doxorubicin would be essential to help prevent heart damage. The drug is used to treat many types of solid tumors and blood cancers, in which the process of administration can enter heart cells by hitchhiking on a specific kind of protein that functions as a transporter to move a drug from the blood into heart cells. By introducing another anti-cancer drug in advance of the chemo, the researchers were able to block the transporter protein, effectively stopping doxorubicin delivery to those cardiac cells. This added drug, nilotinib, has been previously found to inhibit other connected transport proteins.

Jan 2021 Ancora Heart, Inc., a firm advancing a novel therapy to address heart failure, announced the enrollment of the primary patient in the CORCINCH-HF pivotal trial, which is considered to assess the safety and effectiveness of the AccuCinch Ventricular Restoration System in patients who have symptomatic heart failure (H.F.) with reduced ejection fraction (HFrEF). This investigation is being carried out to back the submission of a Premarket Approval (PMA) bid to the U.S. Food and Drug Administration (FDA).

Report Overview

By Type

• Beta-Blockers


• ACE Inhibitors


• Angiotensin-Receptor Neprilysin Inhibitors (ARNI)


• Angiotensin Receptor Blockers (ARBs)


• Diuretic


• Others

By End-User

• Hospitals


• Specialty Centers